| [1] |
Christensen TD, Maag E, Larsen O, et al. Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer[J]. JHEP Rep, 2023, 5(3): 100648.
|
| [2] |
Sinha SR, Prakash P, Singh RK, et al. Assessment of tumor markers CA19-9, CEA, CA125, and CA242 for the early diagnosis and prognosis prediction of gallbladder cancer[J]. World J Gastrointest Surg, 2022, 14(11): 1272-1284.
|
| [3] |
Yin BW, Dnistrian A, Lloyd KO. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene[J]. Int J Cancer, 2002, 98(5): 737-740.
|
| [4] |
段海章, 陈进忠, 石岩, 等. MUC1和MUC16在胆囊癌中的表达及临床意义[J]. 现代肿瘤医学, 2018, 26(18): 2892-2896.
|
| [5] |
Carrasco C, Tittarelli A, Paillaleve N, et al. The evaluation of 17 gastrointestinal tumor markers reveals prognosis value for MUC6, CK17, and CD10 in gallbladder-cancer patients[J]. Diagnostics (Basel), 2021, 11(2): 153.
|
| [6] |
He Y, Xue C, Yu Y, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer[J]. Cancer Manag Res, 2018, 10: 3857-3865.
|
| [7] |
Goodall GJ, Wickramasinghe VO. RNA in cancer[J]. Nat Rev Cancer, 2021, 21(1): 22-36.
|
| [8] |
Liu N, Chang CW, Steer CJ, et al. MicroRNA-15a/16-1 prevents hepatocellular carcinoma by disrupting the communication between Kupffer cells and regulatory T cells[J]. Gastroenterology, 2022, 162(2): 575-589.
|
| [9] |
Yan X, Yang P, Liu H, et al. miR-4461 inhibits the progression of gallbladder carcinoma via regulating EGFR/AKT signaling[J]. Cell Cycle, 2022, 21(11): 1166-1177.
|
| [10] |
Hu X, Zhang J, Bu J, et al. MiR-4733-5p promotes gallbladder carcinoma progression via directly targeting Kruppel like factor 7[J]. Bioengineered, 2022, 13(4): 10691-10706.
|
| [11] |
Huang X, He M, Huang S, et al. Circular RNA circERBB2 promotes gallbladder cancer progression by regulating PA2G4-dependent rDNA transcription[J]. Mol Cancer, 2019, 18(1): 166.
|
| [12] |
Zhang N, Li J, Sun H, et al. Circ_0008234 regulates the biological process of gallbladder carcinoma by targeting the miR-204-5p/FGFR2 axis[J]. Histol Histopathol, 2022: 18538.
|
| [13] |
Wang S, Zhang Y, Cai Q, et al. Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression[J]. Mol Cancer, 2019, 18(1): 145.
|
| [14] |
Hu YP, Jin YP, Wu XS, et al. LncRNA-HGBC stabilized by HuR promotes gallbladder cancer progression by regulating miR-502-3p/SET/AKT axis[J]. Mol Cancer, 2019, 18(1): 167.
|
| [15] |
Chen J, Yu Y, Li H, et al. Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer[J]. Mol Cancer, 2019, 18(1): 33.
|
| [16] |
Shen N, Zhang D, Yin L, et al. Bile cell-free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer[J]. Oncol Rep, 2019, 42(2): 549-560.
|
| [17] |
Yang P, Song F, Yang X, et al. Exosomal microRNA signature acts as an efficient biomarker for non-invasive diagnosis of gallbladder carcinoma[J]. iScience, 2022, 25(9): 104816.
|
| [18] |
张一鉴, 刘颖斌. Journal of Hepatology|利用单细胞RNA测序发现在ErbB通路突变的胆囊癌中存在MDK依赖免疫抑制微环境[J]. 临床肝胆病杂志, 2022, 38(2): 281.
|
| [19] |
Li M, Liu F, Zhang F, et al. Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: A whole-exome sequencing analysis[J]. Gut, 2019, 68(6): 1024-1033.
|
| [20] |
Yang M, Zhao Y, Li Y, et al. Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase Ⅱ trial[J]. BMJ Open, 2023, 13(2): e061892.
|
| [21] |
Chen X, Wang D, Liu J, et al. Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes[J]. J Immunother Cancer, 2021, 9(11): e003214.
|